VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Leveraging technology to detect and mitigate CAR-T therapy-related toxicity remotely

Surbhi Sidana, MD, Mayo Clinic, Stanford, CA, discusses the possibility of detecting and mitigating adverse events caused by CAR-T therapy including cytokine release syndrome (CRS) and neurotoxicity remotely using medical-grade devices to reduce the time that patients spend in the hospital. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter